Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2026)

Recursion Pharmaceuticals (RXRX) has 5 years of Operating Leases data on file, last reported at $42.8 million in Q1 2026.

• Quarterly Operating Leases fell 23.53% year-over-year to $42.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 23.53% YoY) and the FY2025 annual result came in at $46.6 million, down 30.64% from the prior year.
• Operating Leases eased to $42.8 million in Q1 2026, from $46.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $88.8 million in Q2 2024 to a low of $42.8 million in Q1 2026.
• A 5-year average of $52.5 million and a median of $50.0 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases soared 73.82% — and 2025, when it sank 39.85%.
• Tracing RXRX's Operating Leases over 5 years: stood at $44.4 million in 2022, then fell by 2.26% to $43.4 million in 2023, then soared by 54.9% to $67.2 million in 2024, then sank by 30.64% to $46.6 million in 2025, then retreated by 8.16% to $42.8 million in 2026.
• The last three Operating Leases figures came in at $42.8 million (Q1 2026), $46.6 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.